The most recent short interest data has been released for the 12/15/2017 settlement date, which shows a 4,831,803 share decrease in total short interest for Array BioPharma Inc. (ARRY), to 15,831,594, a decrease of 23.38% since 11/30/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for ARRY at the 12/15/2017 settlement increased to 3,128,678, as compared to 2,806,431 at the 11/30/2017 report. That brought "days to cover" down to 5.06, a 31.27% decrease from the 7.36 days to cover calculated at the previous short interest data release.The below chart shows the historical "days to cover" for ARRY at previous short interest release dates: A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where ARRY had been shorted as a hedge. The chart below shows the one year performance of ARRY shares, versus its 200 day moving average. Looking at this chart, ARRY's low point in its 52 week range is $6.73 per share, with $13.40 as the 52 week high point — that compares with a last trade of $12.83. According to the ETF Finder at ETF Channel, ARRY makes up 1.73% of the SPDR S&P Biotech ETF (XBI) which is higher by about 0.3% on the day Thursday.